Brief: Journey Medical Corporation Enters Into An Exclusive License Agreement With Maruho Co., Ltd. For Qbrexza® In South Korea And Other Asian Nations
06/09/2023 16:17
Journey Medical Corp DERM.O :
* ORATION ENTERS INTO AN EXCLUSIVE LICENSE AGREEMENT WITH
MARUHO
CO., LTD. FOR QBREXZA® IN SOUTH KOREA AND OTHER ASIAN NATIONS
* UNDER TERMS OF AGREEMENT, JOURNEY MEDICAL WILL RECEIVE A
$19
MILLION NONREFUNDABLE UPFRONT PAYMENT
* JOURNEY IS STILL ELIGIBLE TO RECEIVE CERTAIN MILESTONES
PAYMENTS, TOTALING UP TO $45 MILLION
Source text for Eikon: ID:nGNX7npYmY
Further company coverage: DERM.O
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi